^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT overexpression

    i
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors (NCT00859937)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/20/2018
    Initiation :
    03/16/2009
    Primary completion :
    01/30/2013
    KIT
    |
    KIT expression • KIT overexpression
    |
    dasatinib